DOI:
10.1055/s-00000069
Seminars in Liver Disease
LinksClose Window
References
Finn RS, Kudo M, Cheng A-L. et al.
59PD - Final analysis of serum biomarkers in patients (pts) from the phase III study of lenvatinib (LEN) vs sorafenib (SOR) in unresectable hepatocellular carcinoma (uHCC) [REFLECT].
Ann Oncol 2018;
29 (Suppl. 08) VIII17-18
Search in:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.